Healthcare Biz Recap: Achillion’s Direct OFFERING, Pfizer To PRESENT In Vienna

Smallcap firm StemCells, Inc. (NASDAQ:STEM) shares continue Thursday’s ride, following the unveiling of a plan that supplies data from a Phase I/II clinical trial which tests its stem-cell therapy that will be used in the treatment of chronic spinal-cord injuries, at the International Spinal Cord Society’s annual scientific meeting.

Don’t Miss: Are Bears WRONG About Facebook?

Shares of Sarepta Therapeutics, Inc. (SRPT) pop again following their 4.3 percent gain on Thursday. Chatter regarding the firm’s Eteplirsen treatment for Duchenne muscular dystrophy has been hot, and includes a report by a news station in Missouri about a boy showing significant improvement after using the drug in clinical trials. Options activity in the stock has been active, with call volume jumping by 700 percent over its daily average.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares soared Friday following the announcement of a registered direct offering , selling 6.4 million shares to funds managed QVT Financial at $6.57 each. Net proceeds from the sale should reach approximately $41.8 million.

Pfizer Inc. (NYSE:PFE) will present on three scientific data at the 2012 European Respiratory Society Congress in Vienna, which begins Saturday. One topic will focus on its Spiriva handiHaler, which should exhibit statistically significant improvement over a placebo in patients suffering from chronic obstructive pulmonary disease.

Don’t Miss: Are Home Prices RECOVERING?

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>